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The Detroit Keloid Scale:
A Validated Tool for Rating Keloids
Alexis B. Lyons, MD,1 David M. Ozog, MD,1,* Henry W. Lim, MD,1 Kate Viola, MD,1
Amy Tang, PhD,2 and Lamont R. Jones, MD, MBA3
Abstract
Background: Comparing keloid treatment modalities and assessing response to treatments may be predicted by a better classiﬁcation system.
Objectives: To develop and validate the Detroit Keloid Scale (DKS), a standardized method of keloid
assessment.
Methods: Forty-seven physicians were polled to develop the DKS. The scale was validated in 52 patients
against the Vancouver Scar Scale (VSS), Patient and Observer Scar Assessment Scale (POSAS), and Dermatology Life Quality Index (DLQI).
Results: The inter-rater reliability was ‘‘substantial’’ for observer DKS and only ‘‘moderate’’ for VSS and observer POSAS (intraclass correlation coefﬁcient were 0.80, 0.60, and 0.47, respectively). Pearson’s correlation
indicated ‘‘moderate’’ association between observer DKS with observer POSAS (q = 0.56, p < 0.001) and ‘‘substantial’’ relationship between observer DKS and VSS (q = 0.63, p < 0.001). Pearson’s correlation indicated
‘‘moderate’’ association between patient portion of DKS and patient portion of POSAS and patient portion
of the DKS and DLQI (0.61 and 0.60, respectively, p < 0.05). DKS total score consistently showed signiﬁcant
‘‘substantial’’ relationship with POSAS total score (q = 0.65, p < 0.001).
Conclusions: The DKS offers a validated keloid-speciﬁc outcome measure for comparing keloid treatments.

which were not included when the most popular scar
outcome instruments were designed.
Objective measurements (e.g., ultrasound) of various
clinical parameters have been explored in the past to
bring objectivity to scar rating systems; however, they
often examined hypertrophic scars and did not include
those with keloids.4 Keloids differ from hypertrophic
scars in that they are characterized by horizontal growth
beyond the boundary of the original wound and represent
a complex pathomechanistic and treatment conundrum.5
Moreover, because they disproportionately affect people

Introduction
There is large heterogeneity in the literature when it
comes to outcome measures for scars.1,2 Outcome measures for scars can include subjective components and
objective measurements.3 In fact, a recent systematic review identified a total of 40 disease outcome measures
that were used in 41 randomized controlled trials.1 These
range from pliability, firmness, color, thickness, vascularity, surface area, and height among others.2 This heterogeneity makes it difficult to compare outcomes of clinical
trials and response to treatments, particularly for keloids,
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KEY POINTS
Question: What are the features of keloid scars that affect
patients and their treatments?
Findings: A new scale was created and compared with existing outcome measures with good success.
Meaning: This new scale, the Detroit Keloid Scale, may allow
providers to better compare patients with keloids, and the effect of their treatments, leading to research that can improve
outcomes.

with skin of color (SOC), common outcome scar scales
that often include components such as vascularity are difficult to apply broadly to keloids.
The most commonly used scar outcome measures are
the Vancouver Scar Scale (VSS)6 and the Patient and
Observer Scar Assessment Scale (POSAS).7 The VSS,
which was developed to rate burn scars, analyzes vascularity, thickness, pliability, and pigmentation by an
observer, whereas the POSAS incorporates these attributes plus surface area assessed by an observer as well
as pain, itching, color, stiffness, thickness, and relief
assessed by the patient.
Although the POSAS and VSS have been utilized to
evaluate keloids,8 these were not designed specifically
with keloids in mind. The Dermatology Life Quality
Index (DLQI)9 is one of the most consistently utilized
patient-reported outcome measures and quantifies how
dermatologic skin conditions affect patient quality of
life; however, it was not proposed specifically for keloid
scars. The objective of this study was to develop and validate a keloid-specific outcome measure, the Detroit
Keloid Scale (DKS), to better enable clinicians and researchers to compare keloid treatment modalities among
studies and to assess treatment efficacy.
Materials and Methods
Development of the DKS
For development of the DKS, physicians from numerous
specialties attending the third International Keloid Symposium (Beijing, China, April 19–21, 2019)10 and from
Henry Ford Hospital (Detroit, MI) were polled through
an online survey with item reduction to rank each component in order from most important to least important for
the development of the DKS to determine the most important clinical factors when evaluating keloids.
A total of 47 physicians from the following specialties
completed the survey: dermatology (25), plastic surgery
(10), otolaryngology (9), primary care (1), general surgery (1), and oncology (1). The key variables reported
for evaluating keloid severity included pain, area, location, contracture/range of motion, quality of life, pruritus,
and height. These components were compiled into a

Patient Keloid Questionnaire and Observer Keloid
Assessment of the DKS (Fig. 1).
Validation of the DKS
This study was approved by the Institutional Review
Board at Henry Ford Hospital (IRB No. 11927). International Conference of Harmonization Guidelines, Declaration of Helsinki Guidelines, and Good Clinical Practice
were followed in the conduct of this study. Informed consent was obtained before all study procedures. Subjects
with keloid scars completed one study visit, which took
place at Henry Ford Hospital, Detroit, MI at the Department of Dermatology.
Photographs were obtained of the keloid to be
assessed. Patients completed the DLQI and the patient
portion of the DKS and POSAS. Three physicians (two
board-certified dermatologists [D.M.O. and H.W.L.]
and one board-certified otolaryngologist and facial plastic surgeon [L.R.J.]) separately examined each patient’s
keloid in-person and completed the VSS and observer
portion of the DKS and POSAS.
Statistical analysis
Statistical analyses were performed by the department of
public health at Henry Ford Hospital. Inter-rater reliability was defined as ‘‘the extent of agreement between
three observers’’ and was assessed by computing the
intraclass correlation coefficient (ICC) using a two-way
mixed model with measures of consistency. An ICC
within the range of 0–0.20 was considered as ‘‘slight,’’
0.21–0.40 as ‘‘fair,’’ 0.41–0.60 as ‘‘moderate,’’ 0.61–
0.80 as ‘‘substantial,’’ and 0.81–1.0 as ‘‘almost perfect.’’
Pearson’s correlations were used to evaluate the convergent validity where 0.9–1 indicated ‘‘very high’’ correlation, 0.7–0.9 indicated ‘‘high’’ correlation, 0.5–0.7
indicated ‘‘moderate’’ correlation, and below 0.5 indicated ‘‘low’’ correlation. Further, p-values of <0.05 were
considered significant. All statistical analyses were performed by using SAS 9.4 (SAS Institute, Cary, NC).
Results
Fifty-two subjects were evaluated independently by the
same three ABMS board-certified physicians experienced in caring for keloid patients (Fig. 2). The mean
total score of the VSS was 6.0 – 2.3. The mean score
of the observer component of POSAS was 21.2 – 8.2,
and with additional patient component of POSAS was
60.3 – 17.4. The mean score of the observer component
of DKS was 3.3 – 1.5, and with additional patient component of DKS was 6.0 – 3.0. The mean total score of the
DLQI was 5.0 – 4.4.
The inter-rater reliability (Table 1) was ‘‘substantial’’
for observer component of the DKS and ‘‘moderate’’ for
the VSS and observer POSAS (ICC were 0.80, 0.60, and

Fig. 1.

Detroit Keloid Scale.
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Table 2. Correlations between the Detroit Keloid Scale,
Patient and Observer Scar Assessment Scale, Dermatology
Life Quality Index, and Vancouver Scar Scale

Fig. 2. Spectrum of keloid severity in patients
participating in the study: (a) patient with
average Detroit Keloid Scale score of 2.7 and (b)
patient with average Detroit Keloid Scale score
of 11.7.

0.47, respectively). Pearson’s correlation indicated a
‘‘moderate’’ association between the observer component of DKS with observer component of POSAS
(q = 0.56, p < 0.001) and a ‘‘substantial’’ relationship
between the observer component of DKS and VSS
(q = 0.63, p < 0.001) (Table 2).
Pearson’s correlation indicated a ‘‘moderate’’ association between the patient portion of DKS and patient portion of POSAS as well as the patient portion of the DKS
and DLQI (0.61 and 0.60, respectively, p < 0.05). The observer components of the DKS and POSAS showed
‘‘moderate’’ correlations with the patient portions of
DKS and POSAS (rater’s average correlations were
0.47 and 0.50, respectively). In addition, the DKS total
score consistently showed significant ‘‘substantial’’ relationship with POSAS total score (q = 0.65, p < 0.001).
Discussion
The DKS was developed in conjunction with multidisciplinary keloid experts from around the world who treat
diverse patient populations. The most important scale domains were identified, and the scale was finalized with
the survey results. The DKS was successfully validated

Table 1. Inter-rater reliability of the Detroit Keloid Scale,
Patient and Observer Scar Assessment Scale,
and Vancouver Scar Scale
Outcome measure
DKS observer
DKS total
POSAS observer
POSAS total
VSS

ICC (95% CI)
0.801
0.951
0.466
0.877
0.599

(0.664–0.884)
(0.904–0.973)
(0.226–0.655)
(0.735–0.937)
(0.438–0.733)

CI, confidence interval; DKS, Detroit Keloid Scale; ICC, intraclass correlation coefficient; POSAS, Patient and Observer Scar Assessment Scale;
VSS, Vancouver Scar Scale.

Pearson’s correlation
coefficient (95% CI)

p

0.56 (0.44–0.66)

<0.001

0.63 (0.52–0.72)
0.66 (0.57–0.74)
0.61 (0.50–0.70)

<0.001
<0.001
<0.001

0.60 (0.40–0.75)
0.65 (0.54–0.73)

<0.001
<0.001

Observer component DKS vs.
observer component POSAS
Observer component DKS vs. VSS
Observer component POSAS vs. VSS
Patient component DKS vs. patient
component of POSAS
Patient component DKS vs. DLQI
Total DKS vs. Total POSAS
DLQI, Dermatology Life Quality Index.

against the VSS, POSAS, and DLQI. The observer
inter-rater reliability of the DKS was superior to both
the VSS and POSAS.
The findings from development of the DKS are consistent with and extend from prior reports, including the
Japan Scar Workshop ( JSW).11 The JSW created the
JSW Scar Scale ( JSS), but in contrast to DKS, the JSS
contains no patient-reported outcomes and aimed to diagnose and distinguish between keloids, hypertrophic scars,
and mature scars.11
Other scoring systems, including the DLQI, have
only patient-reported outcomes whereas some, including the VSS, have only observer components. Although
the POSAS has both patient-reported and observer assessments, it is not specific for keloid scars, which are
biologically distinct from hypertrophic scars, and disproportionally affect SOC patients. Thus, the DKS was
created to incorporate patient-reported and observer assessments to meet the unmet need for a keloid-specific
outcome measurement tool.
In addition, objective measurement tools including ultrasound have been used to measure factors such as vascularity,4 but these can often be costly, time consuming,
and require specialized training to use in clinical practice
and trials.3 Furthermore, vascularity was not included in
DKS as it is not a prominent feature and can be difficult to
assess in patients with SOC, the predominant group that
develops keloids.
The observer inter-rater reliability of the DKS was superior to both the VSS and POSAS. This suggests that the
DKS could be better for use in multicenter clinical trials
and for those involving multiple raters and different specialties. In addition, the ‘‘almost perfect’’ DKS inter-rater
reliability may lead to quick adoption as the standard tool
for assessing keloid clinical trial outcomes.
Limitations to this study included that it was a singlecenter study, and there was no intra-rater reliability analysis as patients were seen at only one visit. In addition, it
remains to be seen the extent that the DKS can pick up
smaller changes before and after treatment in patients
with more severe keloids.

DETROIT KELOID SCALE

In conclusion, the DKS offers a validated keloidspecific outcome measure for standardizing and comparing results. This will provide physicians, researchers, and
other health care providers with a tool to better compare
keloid treatment modalities. Further studies should examine DKS over time and compare results using DKS before
and after treatment as well as between different treatment
modalities.
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